Keywords: roche, mabthera, approved, eu, hoffmann-la, says, received
Roche's MabThera Approved In The EU
Article | 04 June 1998
Hoffmann-La Roche says that it has received approval from the EuropeanCommission to market its anti-CD20 monoclonal antibody MabThera (rituximab) for ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- Elan makes "transformational" acquisitions and a divestment
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- SciClone gains China rights to Zensun's Neucardin
